Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22c72bd5aad51a8

Jump to content

// Workers AI · dad joke modeIs Miriam Merad a good baker? She's a mer-ad for cake.

From Wikipedia, the free encyclopedia
Miriam Merad
Born1969 (age 56–57)
Paris, France
Education
Known for
  • Research on macrophage and dendritic cell biology
  • Tissue-resident macrophages
  • Myeloid cells in cancer and inflammatory disease
Title· Dean for Translational Research and Therapeutic Innovation

· Director, Marc and Jennifer Lipschultz Precision Immunology Institute

· Chair, Department of Immunology and Immunotherapy

· Robin Chemers Neustein Professor of Immunology
Scientific career
Fields
InstitutionsIcahn School of Medicine at Mount Sinai

Miriam Merad (born 1969)[1] is an Algerian physician-scientist and immunologist whose research examines how myeloid cells regulate health and disease. She serves as Dean for Translational Research and Therapeutic Innovation and is Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY.

Merad is known for her research on the macrophage and dendritic cell arms of the myeloid lineage, including demonstrating the developmental origins of tissue-resident macrophages and revealing how distinct macrophage populations acquire specialized functions in different tissues. Her work has advanced understanding of how myeloid cells regulate tissue and organ development and function, inflammatory disease, and immune responses to cancer.

For these contributions, Merad was elected to the United States' National Academy of Sciences in 2020[2] and National Academy of Medicine in 2023.[3]

Education and career

[edit]

Miriam Merad earned her M.D. from the medical school at the University of Algiers. She completed residency in hematology and oncology at Paris Diderot University[4] and obtained a Master's degree in Biotechnology from Paris Diderot, then moved to Stanford University and earned a PhD in the laboratory of Edgar Engleman.[5] Her clinical training was in hematology/oncology and bone marrow transplantation at Hôpital Saint-Louis and Institut Gustave Roussy.

Merad collaborated with Irving Weissman at Stanford[6] with a focus on macrophage and dendritic cell ontogeny.[citation needed] She was recruited by ISMMS in 2004, and in 2014 was appointed an Endowed Chair in Cancer Immunology.[7] In 2016, she was appointed Director of the Immunology Institute,[8] and in August 2023, she became founding Chair of the Department of Immunology and Immunotherapy. The department focuses on immune system biology and its effects on health and disease. In April 2024, she was named Dean for Translational Research and Therapeutic Innovation.[9]

Research

[edit]

Merad's early work identified mechanisms controlling the development and identity of tissue-resident dendritic cells and macrophages. Her laboratory established the embryonic origin of tissue-resident macrophages,[10] microglia,[11] and Langerhans cells.[12] These cells contribute to synaptic pruning, gut peristalsis, fat metabolism, and vascular integrity. Her team identified tissue-resident CD103+ dendritic cells, which specialize in anti-viral and anti-tumor immunity.

Merad's group examines how myeloid cell subsets drive inflammatory diseases. In 2021, Bigenwald, et al., reported that mitogen-activated protein kinase pathway mutations trigger senescence in hematopoietic progenitors. This skews differentiation toward mononuclear phagocytes and causes multisystem Langerhans Cell Histiocytosis.[13] In 2022, Chen, et al., and others reported that severe COVID-19 reduces tissue-resident lung alveolar macrophages, which aid repair, while increasing inflammatory monocytes and monocyte-derived macrophages.[14]

Merad's laboratory explores dendritic cells and macrophages in the tumor microenvironment.[1] Two macrophage lineages she defined appear in tumors. Their origins dictate roles in shaping the microenvironment. In human lung tumors, Casanova-Acebes, et al., reported in 2021 that tissue-resident macrophages cluster near early tumor cells. They increase invasiveness and activate regulatory T cells that shield tumors from immunity.[15] As tumors grow, tissue-resident macrophages shift to the periphery. Monocyte-derived macrophages then dominate.

In 2023, Park, et al., and others reported that TREM2 tumor macrophages suppress immunity. They limit natural killer cell recruitment and activity in lung adenocarcinoma models.[16] In 2020, Maier, et al., reported mature dendritic cells enriched in immunoregulatory molecules (mregDCs). These limit responses to immune checkpoint blockade.[17] In 2023, Magen, et al., and others reported niches where mregDCs operate in tumors.[18]

Merad's contributions to understanding the central role of myeloid cells in tumor development and immunity have been recognized with international awards, including the William B. Coley Award[19], the Sjöberg Prize[20] and the Leopold Griffuel Prize[21].

In 2024, Park, et al., and others reported that aging shifts macrophages from protectors to disease drivers. They fuel cancer via immunosuppressive programs[22] and promote neurodegeneration via senescent monocytes. In 2025, Park, et al., reported strategies to reprogram aging-linked immune cells for healthier longevity.[23] Merad led a semi-finalist team in the XPRIZE Healthspan competition.[24] Merad co-founded the International Immunoschool in 2015 with researchers from Sorbonne University in Paris, France, and University of São Paulo in Brazil.[25] She published on cancer immunotherapy trials,[26] Long COVID classification,[27] immigrants' role in U.S. science,[28] and experiences as a mother scientist.[29]

Awards and honors

[edit]

Notable publications

[edit]

Primary research

[edit]

Reviews and perspectives

[edit]

References

[edit]
  1. 1 2 Azvolinsky, Anna (April 1, 2019). "Cancer Vaxxer: A Profile of Miriam Merad". the-scientist.com. Retrieved June 15, 2025.
  2. ↑ "2020 NAS Election". www.nasonline.org. Retrieved 28 April 2020.
  3. ↑ "National Academy of Medicine Elects 100 New Members". www.nam.edu/. 9 October 2023. Retrieved 11 October 2023.
  4. ↑ "miriam-merad, MD, PhD". icahn.mssm.edu. Retrieved 3 June 2019.
  5. ↑ "Engleman Trainees 1983-present" (PDF). Archived from the original (PDF) on 17 December 2019. Retrieved 3 June 2019.
  6. ↑ "Irving L. Weissman, MD". Retrieved 6 Dec 2022.
  7. ↑ "miriam-merad, MD/PhD". icahn.mssm.edu. Archived from the original on 31 May 2019. Retrieved 3 June 2019.
  8. ↑ "The Tisch Cancer Institute and Precision Immunology Institute at Mount Sinai Launch Center for Computational Immunology". www.mountsinai.org/. Retrieved 15 Dec 2022.
  9. ↑ "Icahn School of Medicine at Mount Sinai Names Miriam Merad, MD, PhD, as Dean for Translational Research and Therapeutic Innovation". www.newswise.com. Retrieved 2024-04-30.
  10. ↑ Hashimoto, Daigo; Chow, Andrew; Noizat, Clara; Teo, Pearline; Beasley, Mary Beth; Leboeuf, Marylene; Becker, Christian D.; See, Peter; Price, Jeremy; Lucas, Daniel; Greter, Melanie; Mortha, Arthur; Boyer, Scott W.; Forsberg, E. Camilla; Tanaka, Masato; Van Rooijen, Nico; García-Sastre, Adolfo; Stanley, E. Richard; Ginhoux, Florent; Frenette, Paul S.; Merad, Miriam (2013). "Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal Contribution from Circulating Monocytes". Immunity. 38 (4): 792–804. doi:10.1016/j.immuni.2013.04.004. PMC 3853406. PMID 23601688.
  11. ↑ Ginhoux, Florent; Greter, Melanie; Leboeuf, Marylene; Nandi, Sayan; See, Peter; Gokhan, Solen; Mehler, Mark F.; Conway, Simon J.; Ng, Lai Guan; Stanley, E. Richard; Samokhvalov, Igor M.; Merad, Miriam (2010). "Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages". Science. 330 (6005): 841–845. Bibcode:2010Sci...330..841G. doi:10.1126/science.1194637. PMC 3719181. PMID 20966214.
  12. ↑ Ginhoux, Florent; Collin, Matthew P.; Bogunovic, Milena; Abel, Michal; Leboeuf, Marylene; Helft, Julie; Ochando, Jordi; Kissenpfennig, Adrien; Malissen, Bernard; Grisotto, Marcos; Snoeck, Hans; Randolph, Gwendalyn; Merad, Miriam (2007). "Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state". The Journal of Experimental Medicine. 204 (13): 3133–3146. doi:10.1084/jem.20071733. PMC 2150983. PMID 18086862. Retrieved 11 May 2022.
  13. ↑ Bigenwald, Camille; Le Berichel, Jessica; Wilk, C. Matthias; Chakraborty, Rikhia; Chen, Steven T.; Tabachnikova, Alexandra; Mancusi, Rebecca; Abhyankar, Harshal; Casanova-Acebes, Maria; Laface, Ilaria; Akturk, Guray; Jobson, Jenielle; Karoulia, Zoi; Martin, Jerome C.; Grout, John; Rafiei, Anahita; Lin, Howard; Manz, Markus G.; Baccarini, Alessia; Poulikakos, Poulikos I.; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; McClain, Kenneth L.; Picarsic, Jennifer; Allen, Carl E.; Merad, Miriam (2021). "BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology". Nature Medicine. 27 (5): 851–861. doi:10.1038/s41591-021-01304-x. PMC 9295868. PMID 33958797.
  14. ↑ Chen, Steven T.; et al. (2022). "A shift in lung macrophage composition is associated with COVID-19 severity and recovery". Science Translational Medicine. 14 (662) eabn5168. doi:10.1126/scitranslmed.abn5168. PMC 10117220. PMID 36103512.
  15. ↑ Casanova-Acebes, María; Dalla, Erica; Leader, Andrew M.; Leberichel, Jessica; Nikolic, Jovan; Morales, Blanca M.; Brown, Markus; Chang, Christie; Troncoso, Leanna; Chen, Steven T.; Sastre-Perona, Ana; Park, Matthew D.; Tabachnikova, Alexandra; Dhainaut, Maxime; Hamon, Pauline; Maier, Barbara; Sawai, Catherine M.; Agulló-Pascual, Esperanza; Schober, Markus; Brown, Brian D.; Reizis, Boris; Marron, Thomas; Kenigsberg, Ephraim; Moussion, Christine; Benaroch, Philippe; Aguirre-Ghiso, Julio A.; Merad, Miriam (2021). "Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells". Nature. 595 (7868): 578–584. Bibcode:2021Natur.595..578C. doi:10.1038/s41586-021-03651-8. PMC 8923521. PMID 34135508.
  16. ↑ Park, Matthew D.; et al. (2023). "TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer". Nature Immunology. 24 (5): 792–801. doi:10.1038/s41590-023-01475-4. PMC 11088947. PMID 37081148.
  17. ↑ Maier, Barbara; Leader, Andrew M.; Chen, Steven T.; Tung, Navpreet; Chang, Christie; Leberichel, Jessica; Chudnovskiy, Aleksey; Maskey, Shrisha; Walker, Laura; Finnigan, John P.; Kirkling, Margaret E.; Reizis, Boris; Ghosh, Sourav; d'Amore, Natalie Roy; Bhardwaj, Nina; Rothlin, Carla V.; Wolf, Andrea; Flores, Raja; Marron, Thomas; Rahman, Adeeb H.; Kenigsberg, Ephraim; Brown, Brian D.; Merad, Miriam (2020). "A conserved dendritic-cell regulatory program limits antitumour immunity". Nature. 580 (7802): 257–262. Bibcode:2020Natur.580..257M. doi:10.1038/s41586-020-2134-y. PMC 7787191. PMID 32269339.
  18. ↑ Magen, Assaf; et al. (2023). "Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma". Nature Medicine. 29 (6): 1389–1399. doi:10.1038/s41591-023-02345-0. PMC 11027932. PMID 37322116.
  19. ↑ "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Archived from the original on 31 May 2019. Retrieved 31 May 2019.
  20. ↑ "Sjöberg Laureate discovered new targets for cancer therapies in the immune system". YouTube. 12 February 2025. Retrieved 13 February 2025.
  21. ↑ "Les lauréats des Prix Fondation ARC Léopold Griffuel". Retrieved 10 February 2025.
  22. ↑ Park, Matthew D.; et al. (2024). "Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis". Science. 386 (6720) eadn0327. Bibcode:2024Sci...386n0327P. doi:10.1126/science.adn0327. PMC 7616710. PMID 39236155.
  23. ↑ Park, Matthew D.; Yatim, Nader; Zhang, Jing; Cho, Byuri Angela; Yoo, Seong-Keun; Schaefer, Maximilian M.; Chowell, Diego; Puleston, Daniel J.; Merad, Miriam (2025). "Restoring resident tissue macrophages to combat aging and cancer". Nature Aging. 5 (8): 1383–1392. doi:10.1038/s43587-025-00898-y. PMID 40813807. Retrieved 4 September 2025.
  24. ↑ "Mount Sinai Researchers in Semifinals of $101 Million XPRIZE Healthspan, a Competition Seeking Innovative Approaches to Aging Well". www.globenewswire.com/ (Press release). 12 May 2025. Retrieved 2025-09-04.
  25. ↑ Vabret, Nicolas; Mateus-Tique, Jaime; Salmon, Hélène; Martin, Jérôme C.; Mateo, Véronique; Serrano, Sandra; Lemoine, François; Chammas, Roger; Merad, Miriam (2024). "Online immunology education for a global world". Nature Reviews Immunology. 24 (9): 615–616. doi:10.1038/s41577-024-01066-w. PMID 38997523. Retrieved 4 September 2025.
  26. ↑ Marron, Thomas U.; Galsky, Matthew D.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Yankelevitz, David; Doroshow, Deborah; Guttman-Yassky, Emma; Ungar, Benjamin; Mehandru, Saurabh; Golas, Benjamin J.; Labow, Daniel; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Buckstein, Michael; Song, Xiaoyu; Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Tewari, Ashutosh; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam (2022). "Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery". Nature Medicine. 28 (4): 626–629. doi:10.1038/s41591-022-01681-x. PMC 9901535. PMID 35347282.
  27. ↑ Mehandru, Saurabh; Merad, Miriam (2022). "Pathological sequelae of long-haul COVID". Nature Immunology. 23 (2): 194–202. doi:10.1038/s41590-021-01104-y. PMC 9127978. PMID 35105985.
  28. ↑ Brown, Brian D.; Leader, Andrew M.; Vilcek, Jan; Merad, Miriam (2020). ""America First" Will Destroy U.S. Science". Cell. 183 (4): 841–844. doi:10.1016/j.cell.2020.09.025. PMC 7500439. PMID 32949492.
  29. ↑ Merad, Miriam (2020). "Reflections from a mother scientist". Nature Medicine. 26 (9): 1316. doi:10.1038/s41591-020-1052-8. PMID 32839622. Retrieved 12 May 2022.
  30. ↑ "Merad, Miriam". Austrian Academy of Sciences. Retrieved 7 July 2026.
  31. ↑ "Merad, Miriam". Accademia Nazionale dei Lincei. Accademia Nazionale dei Lincei. Retrieved 7 July 2026.
  32. ↑ "Miriam Merad, MD, PhD, Awarded French Knighthood for Pioneering Contributions to Science and Medicine". Retrieved 4 September 2025.
  33. ↑ "Sjöberg Laureate discovered new targets for cancer therapies in the immune system". YouTube. 12 February 2025. Retrieved 13 February 2025.
  34. ↑ "CLASS OF 2025". Retrieved 10 February 2025.
  35. ↑ "Class of 2024". Retrieved 10 February 2025.
  36. ↑ "Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation". 25 October 2024. Retrieved 10 February 2025.
  37. ↑ "Les lauréats des Prix Fondation ARC Léopold Griffuel". Retrieved 10 February 2025.
  38. ↑ "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 9 October 2023. Retrieved 7 July 2026.
  39. ↑ "About the Academy of Immuno-Oncology". Retrieved 15 September 2023.
  40. ↑ "International Union of Immunological Societies". Archived from the original on 12 August 2020. Retrieved 20 February 2020.
  41. ↑ "Miriam Merad". Carnegie Corporation of New York. Retrieved June 25, 2024.
  42. ↑ "Miriam Merad". www.nasonline.org/. Retrieved 12 May 2022.
  43. ↑ "William B. Coley Award". Cancer Research Institute. Retrieved 7 July 2026.
  44. ↑ "Highly Cited Researchers". www.clarivate.com/. Retrieved 6 May 2022.
  45. ↑ "The American Society for Clinical Investigation". Retrieved 3 June 2019.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Miriam_Merad&oldid=1364262041"